K-numberK243878
Device nameCLARUS (700)
ApplicantCarl Zeiss Meditec, Inc.
Product codeQER
Device classClass II
Decision dateApr 17, 2025
DecisionSubstantially Equivalent
Regulation886.1120
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The CLARUS 700 v 1.2 is an ophthalmic imaging device that captures, displays, and stores images of the retina, ocular surface, and visible adnexa to aid in diagnosis and monitoring of eye diseases. It provides true color, autofluorescence, and angiography imaging modes in stereo, widefield, ultra-widefield, and montage fields of view, and uses a slit-scanning methodology with LEDs and laser illumination.

Technological characteristics

The device is based on identical hardware to the predicate v1.1, but adds new capability for simultaneous Fluorescein Angiography (FA) and Indocyanine Green Angiography (ICGA) imaging. Hardware additions include an IR laser lightbox, modified excitation and barrier filters, a second turret filter, and alignment tools. Software v1.2 adds angiography movie capture, ETDRS grid overlays, ICGA boost mode, and 8-up image view. Illumination wavelengths were expanded to support ICGA while maintaining existing modalities.

Test standards cited

ISO 10993-1 (biocompatibility), ISO 10940:2009, ANSI/AAMI ES60601-1:2005/(R)2012, ANSI Z80.36-2021, IEC 60601-1-2:2014, IEC 60825-1:2007, IEC 60601-2-22:2012, and IEC 62133:2012. Software verification and validation followed FDA guidance for medical device software.

Substantial equivalence argument

The indications for use, principle of operation (slit-scanning), methodology, anatomical site, target population, and basic device configuration are identical to the predicate device. The new ICGA functionality is integrated solely through targeted hardware and software enhancements that do not alter the fundamental imaging principle or intended use. Clinical testing demonstrated that the new simultaneous FA+ICGA and standalone ICGA modes produce high-quality angiography images clinically acceptable by independent graders, and non-clinical testing confirmed the system meets all specifications. Since differences are limited to new imaging modalities that pose no new safety or effectiveness concerns, substantial equivalence is established.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →